Atracurium : interactions médicamenteuses

Atracurium, bloquant neuromusculaire, présente 64 interactions documentées dans les notices FDA et les fiches d'information que nous indexons : 8 de niveau majeur, 33 de niveau modéré, 21 de niveau mineur et 2 cas où une notice ne signale aucune interaction significative. Chaque entrée ci-dessous cite la phrase sur laquelle elle repose. Cette page consacrée à un médicament est un point de départ, pas un verdict sur votre situation.

Interactions d'après la notice

Interactions majeures (8)

  • AlcoolAlcoolMajeure

    Use of atracurium besylate from multiple dose vials containing benzyl alcohol as a preservative is contraindicated in patients with a known hypersensitivity to benzyl alcohol. (notice Atracurium, Contre-indications)

  • NéomycineaminosideMajeure

    The possibility of the occurrence of neuromuscular blockage and respiratory paralysis should be considered if neomycin is administered, especially to patients receiving anesthetics, neuromuscular blocking agents such as tubocurarine, succinylcholine, decamethonium, or in patients receiving massive transfusions of citrate anticoagulated blood. (notice Néomycine, Mise en garde encadrée)

  • PlazomicineaminosideMajeure

    During therapy with ZEMDRI, monitor for adverse reactions associated with neuromuscular blockade, particularly in high-risk patients, such as patients with underlying neuromuscular disorders (including myasthenia gravis) or in patients concomitantly receiving neuromuscular blocking agents [see Warning and Precautions (5.3) ] . (notice Plazomicine, Mise en garde encadrée)

  • QuinineantipaludiqueMajeure

    Avoid concomitant use with neuromuscular blocking agents. (notice Quinine, Mises en garde et précautions)

  • RémifentanilopioïdeMajeure

    In the case of life-threatening muscle rigidity, a rapid onset neuromuscular blocker or naloxone may be administered. (notice Rémifentanil, Mises en garde et précautions)

  • Rocuroniumbloquant neuromusculaireMajeure

    Rocuronium Bromide Injection is contraindicated in patients known to have hypersensitivity (e.g., anaphylaxis) to rocuronium bromide or other neuromuscular blocking agents [see Warnings and Precautions ( 5.2 )] . (notice Rocuronium, Contre-indications)

  • SugammadexMajeure

    Reversal of Neuromuscular Blocking Agents Other Than Rocuronium or Vecuronium Do not use BRIDION to reverse blockade induced by nonsteroidal neuromuscular blocking agents such as succinylcholine or benzylisoquinolinium compounds. (notice Sugammadex, Mises en garde et précautions)

  • Suxaméthoniumbloquant neuromusculaireMajeure

    Atracurium should not be administered until a patient has recovered from succinylcholine-induced neuromuscular block. (notice Atracurium, Interactions médicamenteuses)

Interactions modérées (33)

  • AmikacineaminosideModérée

    Drug Interactions Drugs which may enhance the neuromuscular blocking action of atracurium include: enflurane; isoflurane; halothane; certain antibiotics, especially the aminoglycosides and polymyxins; lithium; magnesium salts; procainamide; and quinidine. (notice Atracurium, Interactions médicamenteuses)

  • BaclofènemyorelaxantModérée

    If other muscle relaxants are used during the same procedure, the possibility of a synergistic or antagonist effect should be considered. (notice Atracurium, Interactions médicamenteuses)

  • CarisoprodolmyorelaxantModérée

    If other muscle relaxants are used during the same procedure, the possibility of a synergistic or antagonist effect should be considered. (notice Atracurium, Interactions médicamenteuses)

  • ChlorzoxazonemyorelaxantModérée

    If other muscle relaxants are used during the same procedure, the possibility of a synergistic or antagonist effect should be considered. (notice Atracurium, Interactions médicamenteuses)

  • Cisatracuriumbloquant neuromusculaireModérée

    Precautions should also be taken in those individuals who have had previous anaphylactic reactions to other neuromuscular blocking agents since cross-reactivity between neuromuscular blocking agents, both depolarizing and non-depolarizing, has been reported in this class of drugs. (notice Atracurium, Mises en garde)

  • ClindamycineantibiotiqueModérée

    • Neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents. (notice Clindamycine, Interactions médicamenteuses)

  • CyclobenzaprinemyorelaxantModérée

    If other muscle relaxants are used during the same procedure, the possibility of a synergistic or antagonist effect should be considered. (notice Atracurium, Interactions médicamenteuses)

  • DantrolènemyorelaxantModérée

    If other muscle relaxants are used during the same procedure, the possibility of a synergistic or antagonist effect should be considered. (notice Atracurium, Interactions médicamenteuses)

  • DéflazacortcorticoïdeModérée

    Myopathy Patients receiving corticosteroids, including EMFLAZA, and concomitant therapy with neuromuscular blocking agents (e.g., pancuronium) or patients with disorders of neuromuscular transmission (e.g., myasthenia gravis) may be at increased risk of developing acute myopathy. (notice Déflazacort, Mises en garde et précautions)

  • Desfluraneanesthésique généralModérée

    Neuromuscular Blocking Agents Anesthetic concentrations of desflurane at equilibrium (administered for 15 or more minutes before testing) reduced the ED 95 of succinylcholine by approximately 30% and that of atracurium and pancuronium by approximately 50% compared to N 2 O/opioid anesthesia (see Table 4). (notice Desflurane, Interactions médicamenteuses)

  • Dextrométhorphane et quinidinemédicament sérotoninergiqueModérée

    Drug Interactions Drugs which may enhance the neuromuscular blocking action of atracurium include: enflurane; isoflurane; halothane; certain antibiotics, especially the aminoglycosides and polymyxins; lithium; magnesium salts; procainamide; and quinidine. (notice Atracurium, Interactions médicamenteuses)

  • FentanylopioïdeModérée

    • Risks of Skeletal Muscle Rigidity and Skeletal Muscle Movement : Manage with neuromuscular blocking agent. (notice Fentanyl, Mises en garde et précautions)

  • GentamicineaminosideModérée

    Drug Interactions Drugs which may enhance the neuromuscular blocking action of atracurium include: enflurane; isoflurane; halothane; certain antibiotics, especially the aminoglycosides and polymyxins; lithium; magnesium salts; procainamide; and quinidine. (notice Atracurium, Interactions médicamenteuses)

  • IncobotulinumtoxinAbloquant neuromusculaireModérée

    Precautions should also be taken in those individuals who have had previous anaphylactic reactions to other neuromuscular blocking agents since cross-reactivity between neuromuscular blocking agents, both depolarizing and non-depolarizing, has been reported in this class of drugs. (notice Atracurium, Mises en garde)

  • Isofluraneanesthésique généralModérée

    Drug Interactions Drugs which may enhance the neuromuscular blocking action of atracurium include: enflurane; isoflurane; halothane; certain antibiotics, especially the aminoglycosides and polymyxins; lithium; magnesium salts; procainamide; and quinidine. (notice Atracurium, Interactions médicamenteuses)

  • LincomycineantibiotiqueModérée

    Drug Interactions Lincomycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents; therefore, it should be used with caution in patients receiving such agents. (notice Lincomycine, Interactions médicamenteuses)

  • Lithiummédicament sérotoninergiqueModérée

    Drug Interactions Drugs which may enhance the neuromuscular blocking action of atracurium include: enflurane; isoflurane; halothane; certain antibiotics, especially the aminoglycosides and polymyxins; lithium; magnesium salts; procainamide; and quinidine. (notice Atracurium, Interactions médicamenteuses)

  • MagnésiumVitamines et minérauxModérée

    Drug Interactions Drugs which may enhance the neuromuscular blocking action of atracurium include: enflurane; isoflurane; halothane; certain antibiotics, especially the aminoglycosides and polymyxins; lithium; magnesium salts; procainamide; and quinidine. (notice Atracurium, Interactions médicamenteuses)

  • MétaxalonemyorelaxantModérée

    If other muscle relaxants are used during the same procedure, the possibility of a synergistic or antagonist effect should be considered. (notice Atracurium, Interactions médicamenteuses)

  • MéthocarbamolmyorelaxantModérée

    If other muscle relaxants are used during the same procedure, the possibility of a synergistic or antagonist effect should be considered. (notice Atracurium, Interactions médicamenteuses)

  • OnabotulinumtoxinAbloquant neuromusculaireModérée

    Precautions should also be taken in those individuals who have had previous anaphylactic reactions to other neuromuscular blocking agents since cross-reactivity between neuromuscular blocking agents, both depolarizing and non-depolarizing, has been reported in this class of drugs. (notice Atracurium, Mises en garde)

  • OrphénadrinemyorelaxantModérée

    If other muscle relaxants are used during the same procedure, the possibility of a synergistic or antagonist effect should be considered. (notice Atracurium, Interactions médicamenteuses)

  • If other muscle relaxants are used during the same procedure, the possibility of a synergistic or antagonist effect should be considered. (notice Atracurium, Interactions médicamenteuses)

  • Pipéracilline et tazobactamantibiotique de la famille des pénicillinesModérée

    Piperacillin and Tazobactam for Injection and Sodium Chloride Injection may prolong the neuromuscular blockade of vecuronium and other non-depolarizing neuromuscular blockers. (notice Pipéracilline et tazobactam, Interactions médicamenteuses)

  • ProcaïnamideantiarythmiqueModérée

    Drug Interactions Drugs which may enhance the neuromuscular blocking action of atracurium include: enflurane; isoflurane; halothane; certain antibiotics, especially the aminoglycosides and polymyxins; lithium; magnesium salts; procainamide; and quinidine. (notice Atracurium, Interactions médicamenteuses)

  • Pyridostigmineinhibiteur de la cholinestéraseModérée

    Depolarizing neuromuscular blocking agents: Increased effect. (notice Pyridostigmine, Interactions médicamenteuses)

  • QuinidineantiarythmiqueModérée

    Drug Interactions Drugs which may enhance the neuromuscular blocking action of atracurium include: enflurane; isoflurane; halothane; certain antibiotics, especially the aminoglycosides and polymyxins; lithium; magnesium salts; procainamide; and quinidine. (notice Atracurium, Interactions médicamenteuses)

  • Sévofluraneanesthésique généralModérée

    When used to supplement alfentanil-N 2 O anesthesia, sevoflurane and isoflurane equally potentiate neuromuscular block induced with pancuronium, vecuronium or atracurium. (notice Sévoflurane, Interactions médicamenteuses)

  • TizanidinemyorelaxantModérée

    If other muscle relaxants are used during the same procedure, the possibility of a synergistic or antagonist effect should be considered. (notice Atracurium, Interactions médicamenteuses)

  • TobramycineaminosideModérée

    Drug Interactions Drugs which may enhance the neuromuscular blocking action of atracurium include: enflurane; isoflurane; halothane; certain antibiotics, especially the aminoglycosides and polymyxins; lithium; magnesium salts; procainamide; and quinidine. (notice Atracurium, Interactions médicamenteuses)

  • Toxine botulinique de type Abloquant neuromusculaireModérée

    Precautions should also be taken in those individuals who have had previous anaphylactic reactions to other neuromuscular blocking agents since cross-reactivity between neuromuscular blocking agents, both depolarizing and non-depolarizing, has been reported in this class of drugs. (notice Atracurium, Mises en garde)

  • Vécuroniumbloquant neuromusculaireModérée

    Precautions should also be taken in those individuals who have had previous anaphylactic reactions to other neuromuscular blocking agents since cross-reactivity between neuromuscular blocking agents, both depolarizing and non-depolarizing, has been reported in this class of drugs. (notice Atracurium, Mises en garde)

  • Vérapamilinhibiteur calciqueModérée

    Neuromuscular Blocking Agents Clinical data and animal studies suggest that verapamil may potentiate the activity of neuromuscular blocking agents (curare-like and depolarizing). (notice Vérapamil, Interactions médicamenteuses)

Mentions mineures (21)

  • Butalbital et paracétamolbarbituriqueMineure

    Atracurium besylate injection, which has an acid pH, should not be mixed with alkaline solutions (e.g., barbiturate solutions) in the same syringe or administered simultaneously during intravenous infusion through the same needle. (notice Atracurium, Mises en garde)

  • Atracurium besylate injection, which has an acid pH, should not be mixed with alkaline solutions (e.g., barbiturate solutions) in the same syringe or administered simultaneously during intravenous infusion through the same needle. (notice Atracurium, Mises en garde)

  • Atracurium besylate injection, which has an acid pH, should not be mixed with alkaline solutions (e.g., barbiturate solutions) in the same syringe or administered simultaneously during intravenous infusion through the same needle. (notice Atracurium, Mises en garde)

  • Atracurium besylate injection, which has an acid pH, should not be mixed with alkaline solutions (e.g., barbiturate solutions) in the same syringe or administered simultaneously during intravenous infusion through the same needle. (notice Atracurium, Mises en garde)

  • Atracurium besylate injection, which has an acid pH, should not be mixed with alkaline solutions (e.g., barbiturate solutions) in the same syringe or administered simultaneously during intravenous infusion through the same needle. (notice Atracurium, Mises en garde)

  • CarbamazépineanticonvulsivantMineure

    N e uromuscular Blocking Agents Resistance to the neuromuscular blocking action of the nondepolarizing neuromuscular blocking agents pancuronium, vecuronium, rocuronium and cisatracurium has occurred in patients chronically administered carbamazepine. (notice Carbamazépine, Interactions médicamenteuses)

  • Digoxineglycoside digitaliqueMineure

    Norepinephrine Dopamine Neuromuscular Blocking Agents Succinylcholine May cause sudden extrusion of potassium from muscle cells causing arrhythmias in patients taking digoxin. (notice Digoxine, Interactions médicamenteuses)

  • Donépézilinhibiteur de la cholinestéraseMineure

    ANTICHOLINESTERASE REVERSAL AGENTS SHOULD BE IMMEDIATELY AVAILABLE. (notice Atracurium, Mises en garde)

  • DoxapramMineure

    In patients who have received neuromuscular blocking agents, doxapram may temporarily mask the residual effects of these drugs. (notice Doxapram, Interactions médicamenteuses)

  • FosphénytoïneanticonvulsivantMineure

    Neuromuscular blocking agents Cisatracurium, pancuronium, rocuronium and vecuronium: resistance to the neuromuscular blocking action of the nondepolarizing neuromuscular blocking agents has occurred in patients chronically administered phenytoin. (notice Fosphénytoïne, Interactions médicamenteuses)

  • Galantamineinhibiteur de la cholinestéraseMineure

    ANTICHOLINESTERASE REVERSAL AGENTS SHOULD BE IMMEDIATELY AVAILABLE. (notice Atracurium, Mises en garde)

  • Mémantine et donépézilinhibiteur de la cholinestéraseMineure

    ANTICHOLINESTERASE REVERSAL AGENTS SHOULD BE IMMEDIATELY AVAILABLE. (notice Atracurium, Mises en garde)

  • MéthohexitalbarbituriqueMineure

    Atracurium besylate injection, which has an acid pH, should not be mixed with alkaline solutions (e.g., barbiturate solutions) in the same syringe or administered simultaneously during intravenous infusion through the same needle. (notice Atracurium, Mises en garde)

  • Néostigmineinhibiteur de la cholinestéraseMineure

    ANTICHOLINESTERASE REVERSAL AGENTS SHOULD BE IMMEDIATELY AVAILABLE. (notice Atracurium, Mises en garde)

  • PhénobarbitalbarbituriqueMineure

    Atracurium besylate injection, which has an acid pH, should not be mixed with alkaline solutions (e.g., barbiturate solutions) in the same syringe or administered simultaneously during intravenous infusion through the same needle. (notice Atracurium, Mises en garde)

  • Atracurium besylate injection, which has an acid pH, should not be mixed with alkaline solutions (e.g., barbiturate solutions) in the same syringe or administered simultaneously during intravenous infusion through the same needle. (notice Atracurium, Mises en garde)

  • PhénytoïneanticonvulsivantMineure

    Neuromuscular blocking agents Cisatracurium, pancuronium, rocuronium and vecuronium: resistance to the neuromuscular blocking action of the nondepolarizing neuromuscular blocking agents has occurred in patients chronically administered phenytoin. (notice Phénytoïne, Interactions médicamenteuses)

  • Physostigmineinhibiteur de la cholinestéraseMineure

    ANTICHOLINESTERASE REVERSAL AGENTS SHOULD BE IMMEDIATELY AVAILABLE. (notice Atracurium, Mises en garde)

  • PrimidoneanticonvulsivantMineure

    Atracurium besylate injection, which has an acid pH, should not be mixed with alkaline solutions (e.g., barbiturate solutions) in the same syringe or administered simultaneously during intravenous infusion through the same needle. (notice Atracurium, Mises en garde)

  • Propofoldépresseur du SNCMineure

    Common Neuromuscular Blocking Agents DIPRIVAN does not cause a clinically significant change in onset, intensity or duration of action of the commonly used neuromuscular blocking agents (e.g., succinylcholine and nondepolarizing muscle relaxants). (notice Propofol, Interactions médicamenteuses)

  • Rivastigmineinhibiteur de la cholinestéraseMineure

    ANTICHOLINESTERASE REVERSAL AGENTS SHOULD BE IMMEDIATELY AVAILABLE. (notice Atracurium, Mises en garde)

Aucune interaction significative signalée (2)

  • Dexmédétomidineagoniste alpha-adrénergiqueAucune interaction

    Neuromuscular Blockers In one study of 10 healthy adult volunteers, administration of PRECEDEX for 45 minutes at a plasma concentration of one ng/mL resulted in no clinically meaningful increases in the magnitude of neuromuscular blockade associated with rocuronium administration. (notice Dexmédétomidine, Interactions médicamenteuses)

  • Ondansétronmédicament allongeant l'intervalle QTAucune interaction

    Alfentanil and Atracurium Ondansetron does not alter the respiratory depressant effects produced by alfentanil or the degree of neuromuscular blockade produced by atracurium. (notice Ondansétron, Interactions médicamenteuses)

Vérifiez Atracurium avec tout ce que vous prenez. Ajoutez votre liste complète ; toutes les paires sont vérifiées en une fois.

Ouvrir dans le vérificateur

Ceci n'est pas un avis médical. Le niveau de gravité reflète la formulation de la notice, pas votre situation. Une alerte « majeure » peut être courante sous surveillance et une alerte « mineure » peut compter à forte dose. Demandez conseil à un pharmacien.